Overview

The First-line Treatment of RCLM With RAS Mutation Was Local Short-course Radiotherapy (SCRT) + PD-1+ Standard Therapy

Status:
Not yet recruiting

Trial end date:
2026-05-01

Target enrollment:

Participant gender:

Summary

To explore the efficacy and safety of radiotherapy followed by PD-1+ standard chemotherapy in the first-line treatment of initial unresectable rectal cancer liver metastases

Phase:

Phase 2

Details

Lead Sponsor:

Fujian Cancer Hospital

Treatments:

Bevacizumab
Calcium
Fluorouracil
Leucovorin
Levoleucovorin
Oxaliplatin